ARTBIO

What ARTBIO does

ARTBIO is a clinical-stage radiopharmaceutical biotechnology company developing a new class of alpha radioligand therapies (ART) for cancer treatment, founded in 2021 and headquartered in Cambridge, Massachusetts. The company's core technology centers on the use of lead-212 (212Pb) as an in vivo generator of alpha-emitting bismuth-212, which the company positions as offering potentially improved efficacy and safety compared to existing beta radioligand therapies. The proprietary AlphaDirect™ platform supports the design, manufacturing, and decentralized distribution of lead-212 based therapies, and the company's lead program AB001 (212Pb-NG001) is currently in Phase 1 clinical trials (the ARTISAN study) for metastatic castration-resistant prostate cancer (mCRPC) at U.S. clinical trial sites including BAMF Health.

Name

ARTBIO

Legal name

ARTBIO, Inc.

Website

https://artbio.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

51–100 employees

Ownership category

akta.pro rank

Product category

Radiopharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy) (HLAIAGAB)

akta.pro secondary industries

Radiopharmaceutical CDMO & Manufacturing (GMP Fill-Finish) (HLAIAGAF), Radiopharmaceutical Manufacturing & CDMO (Synthesis, GMP, Packaging, QA/QC) (EUAKAIAC)

Keywords

• Radiopharmaceutical therapy
• Alpha radioligand therapy
• Targeted cancer treatment
• Radiopharmaceutical development
• Oncology drug development

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Offices6 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Infrastructure, Operations, Supply Chain, Marketing or Sales

Revenue model

1. Pharmaceutical Product Sales: As a clinical-stage company, ARTBIO currently has no revenue. The company is developing targeted alpha radioligand therapies for cancer treatment and will generate revenue through the sale of approved radiopharmaceutical products upon successful clinical development and regulatory approval.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Core offering

ARTBIO is a clinical-stage radiopharmaceutical biotechnology company developing a new class of alpha radioligand therapies (ART) for cancer treatment using Lead-212 (212Pb) as the alpha-emitting isotope. The company's lead program AB001 (212Pb-NG001) targets metastatic castration-resistant prostate cancer and is currently in Phase 1 clinical trials, with additional pipeline programs targeting TNBC, HNSCC, NSCLC, pancreatic cancer, and other solid tumors. The company builds a comprehensive ecosystem including proprietary AlphaDirect™ isotope technology and a decentralized manufacturing network to design, manufacture, and distribute its radioligand therapies.

Product overview

ARTBIO is a clinical-stage radiopharmaceutical company developing a new class of alpha radioligand therapies (ART) for cancer treatment. The company's differentiated pipeline includes lead program AB001 (a Lead-212 based therapy for prostate cancer currently in Phase 1), supported by its proprietary AlphaDirect™ isotope production technology. ARTBIO's approach utilizes Lead-212 as an ideal alpha-emitting isotope and builds a comprehensive manufacturing ecosystem to enable decentralized production of radiopharmaceuticals. Additional pipeline programs include ABD (TNBC, HNSCC), ABA (NSCLC, Pancreas), ABC (Multiple Solid Tumors), and HEARTS (Multiple Solid Tumors), with many more programs in development.

Differentiator

Problem solved

Functional benefit

Brands

• AlphaDirect™: Proprietary isotope technology developed by ARTBIO for producing alpha radioligand therapies.

Products and services

• AB001 (212Pb-NG001) Lead alpha radioligand therapy program using Lead-212 (212Pb) conjugated to a PSMA-targeting ligand for treatment of metastatic castration-resistant prostate cancer (mCRPC). Currently in Phase 1 clinical trials (ARTISAN trial) enrolling both treatment-naïve and 177Lu-PSMA-experienced patients.
• AlphaDirect™ Technology Platform Proprietary isotope production technology platform for the decentralized manufacturing of alpha radioligand therapies using Lead-212. Underpins ARTBIO's lead-212-based radiopharmaceutical portfolio.
• ABD Non-clinical stage alpha radioligand therapy candidate targeting triple-negative breast cancer (TNBC) and head and neck squamous cell carcinoma (HNSCC).
• ABA Non-clinical stage alpha radioligand therapy candidate targeting non-small cell lung cancer (NSCLC) and pancreatic cancer.
• ABC Discovery-stage alpha radioligand therapy candidate targeting multiple solid tumor types.
• HEARTS Discovery-stage alpha radioligand therapy program targeting multiple solid tumor types.

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Four partnerships are on record, tiered major and core.

• OncoinventmajorStrategic or Co-development Partner · 4 December 2024Oncoinvent announced an agreement with ARTBIO to collaborate on radiopharma laboratory facilities, supporting ARTBIO's manufacturing infrastructure development.
• 3B PharmaceuticalsmajorStrategic or Co-development Partner · 14 November 2024ARTBIO entered into a licensing and research partnership with 3B Pharmaceuticals to advance a first-in-class alpha radioligand therapy for solid tumors. This partnership brings together complementary expertise in radiopharmaceutical development.
• Thor MedicalcoreStrategic or Co-development Partner · 29 October 2024Thor Medical and ARTBIO signed a strategic long-term supply agreement for Thorium-228, a critical isotope for ARTBIO's alpha radioligand therapies. This ensures reliable supply of key radioactive material.
• University of Oslo / Oslo Science ParkcoreStrategic or Co-development PartnerARTBIO expanded its radiopharmaceutical R&D capabilities with a move to Oslo Science Park. The company has roots in groundbreaking research conducted at the University of Oslo and Norway's Radium Hospital.

Scale indicators4 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• Lantheus Holdings: Established radiopharmaceutical company with portfolio including diagnostic radiopharmaceuticals and prostate cancer imaging agents (Pylarify). Competes in the broader nuclear medicine ecosystem serving the same clinical sites and patient populations ARTBIO targets.
• Fusion Pharmaceuticals: Clinical-stage radiopharmaceutical company developing targeted alpha therapies (actinium-225). Acquired by AstraZeneca in 2024 for approximately $2.4B, validating M&A appetite for alpha radioligand platforms and representing a potential exit benchmark for ARTBIO.
• ITM Isotope Technologies Munich: Radiopharmaceutical company specializing in medical radioisotopes and targeted radionuclide therapies, including lutetium-177-based products. Competes in the broader radioligand therapy space and shares ARTBIO's manufacturing complexity around isotope production and supply.
• Bayer (Xofigo): Acquired Xofigo (radium-223) — the first commercial alpha-emitting therapy — via Algeta. ARTBIO's scientific co-founders Roy Larsen and Øyvind Bruland invented Xofigo, establishing a direct lineage between Bayer's alpha therapy franchise and ARTBIO's platform.
• Telix Pharmaceuticals: Commercial-stage radiopharmaceutical company with approved PSMA imaging agent (Illuccix) and development pipeline including therapeutic radioligands. Targets the same prostate cancer patient population as ARTBIO's lead AB001 program.
• Novartis (Pluvicto / Radioligand Therapy): Pharma incumbent whose Pluvicto (177Lu-PSMA-617) established the radioligand therapy market in prostate cancer, generating significant commercial revenue. ARTBIO's CEO Emanuele Ostuni was previously at Novartis Oncology, and ARTBIO targets the same prostate cancer indication with a differentiated alpha-emitting approach.

Emerging players

• Advancell: Emerging player developing lead-212-based radiopharmaceuticals in clinical trials, identified in ARTBIO data as a peer competing in the same lead-212 modality and overlapping target antigens.

Direct peers

• Orano Med: Subsidiary of Orano Group developing lead-212 (212Pb) alpha radioligand therapies for cancer. Identified in ARTBIO data as a direct lead-212 competitor with clinical-stage programs targeting PSMA and other tumor-associated antigens.
• Perspective Therapeutics: Clinical-stage radiopharmaceutical company developing lead-212-based alpha radioligand therapies (212Pb-VMT-α-NET for neuroendocrine tumors and 212Pb-VMT01 for melanoma). Identified in ARTBIO data as a direct lead-212 competitor targeting overlapping tumor antigens.

Regional players

• Oncoinvent: Norwegian radiopharmaceutical company developing alpha-emitting therapies (radium-224). Already partners with ARTBIO on radiopharma laboratory facilities, providing manufacturing infrastructure support; shares ARTBIO's Norwegian scientific heritage and radionuclide therapy focus.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/artbio_inc
• LinkedInlinkedin.com/company/artbio-inc

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries4 records

Funding overview

Funding rounds3 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ARTBIO